key: cord-0074344-idbh6jm0
authors: Oleinikov, Andrew V.
title: Malaria Parasite Plasmodium falciparum Proteins on the Surface of Infected Erythrocytes as Targets for Novel Drug Discovery
date: 2022-01-31
journal: Biochemistry (Mosc)
DOI: 10.1134/s0006297922140152
sha: cf62b1a1d1595d25f625a5f10af0d328ec9c6b7b
doc_id: 74344
cord_uid: idbh6jm0

Specific adhesion (sequestration) of Plasmodium falciparum parasite-infected erythrocytes (IEs) in deep vascular beds can cause severe complications resulting in death. This review describes our work on the discovery, characterization, and optimization of novel inhibitors that specifically prevent adhesion of IEs to the host vasculature during severe malaria, especially its placental and cerebral forms. The main idea of using anti-adhesion drugs in severe malaria is to release sequestered parasites (or prevent additional sequestration) as quickly as possible. This may significantly improve the outcomes for patients with severe malaria by decreasing local and systemic inflammation associated with the disease and reestablishing the microvascular blood flow. To identify anti-malarial adhesion-inhibiting molecules, we have developed a high-throughput (HT) screening approach and found a number of promising leads that can be further developed into anti-adhesion drugs providing an efficient adjunct therapy against severe forms of malaria.

Malaria caused by the parasite Plasmodium falci parum is one of the major devastating diseases worldwide, with half a billion cases and up to 0.5 1 million deaths, mostly among young children, yearly. According to the World Health Organization, most deaths result from severe malaria (SM) complications, the major forms of which include cerebral malaria (CM), placental malar ia (PM), respiratory distress, and severe anemia [1] . Currently, there is a noticeable decline in the efficacy of commonly used anti malarial drugs. It should be noted that although still efficient anti malarial drugs rapidly kill the parasite, significant mortality (10 15%) ensues in SM, particularly within 24 h of hospital admission. This happens most likely due to the cytoadherence of infected erythrocytes (IEs) that continues long after the parasites inside the red blood cells have been killed [2] . Unfortunately, novel parasite killing drugs will have the same problem if they do not affect the cytoadhesion of IEs. This strongly justifies the need for the development adjunctive therapies able to prevent and/or reverse the pathophysiological consequences of cytoadherence in SM. Our main objective was to discover, characterize, and optimize novel inhibitors of cytoadhesion of P. falci parum infected erythrocytes to the host vasculature for the treatment of severe forms of malaria (including CM and PM). Below, we review our works in this area.

Most anti malarial drugs target intracellular process es required for the parasite survival and propagation. Such drugs must penetrate into the parasite by crossing several membranes, including erythrocyte plasma mem brane, parasitophorous vacuolar membrane, and parasite plasma membrane. These drugs also have potential side effects, since they may similarly penetrate into the host cells and interfere with the host cellular functions.

Cytoadherence plays an important role in the lifecy cle and virulence of P. falciparum (reviewed in [3] ), the deadliest of human malaria parasites, and is a cause of PM [4] and CM [5 7 ] (figure). It is reasonable to suggest that reducing cytoadherence of IEs to the host vascula ture will have a strong beneficial effect on the host defense against the infection, a hypothesis that can only be tested experimentally. A simple fact that the appearance of anti adhesion antibodies preventing IE cytoadhesion to the placental syncytiotrophoblast in multigravid women is associated with protection against PM pathology [8, 9] indicates that the anti adhesion therapy might be effec tive against at least this severe disease (figure). The anti adhesion activity is considered as an important factor in the development of successful vaccine against PM [10] . Furthermore, we found that >75% immune adults have high levels of antibodies inhibiting adhesion to the ICAM 1 receptor [11] involved in SM and CM (see below). This anti adhesion activity may contribute (along with the ability to opsonize IEs) to the fast recovery of severely sick children injected with IgG from immune adults [12] . The time window for the pharmacological effect of drugs is extremely critical for the survival in SM. The anti adhesion agents working from outside of IEs, will likely have a higher speed of action. In this respect, molecules with a limited ability to penetrate through the plasma membranes and, therefore, to interfere with the host functions, might be especially safe, although they may need to be delivered intravenously, which is well jus tified in the case of life threatening SM episodes. This is extremely important in the treatment of malaria during pregnancy, as the safety of both mother and fetus is the main issue with currently used drugs [13] . Moreover, as IEs bind to functionally relevant parts of host receptors and may inhibit their normal physiological functions [14] , anti adhesion drugs would have an additional posi tive effect on the host. In our opinion, as well as in the opinion of other researchers, anti adhesion drugs may be very efficient and safe for the anti malarial therapy [15, 16] when used as an adjunctive therapy together with parasiticidal drugs (figure). If, by chance, an anti adhe sion drug also has a parasiticidal effect [16] , it would be even more valuable.

P. falciparum is the only malaria parasite species that was clearly shown to efficiently sequester IEs in various organs using host cell surface receptors for adhesion to endothelial cells, uninfected red blood cells, and cells of immune system [17 21] . Cytoadhesion allows IEs to avoid clearance in the spleen (main innate anti malarial mechanism). However, cytoadhesion also leads to the vascular occlusion that strongly correlates with disease severity [22] and inflammation of endothelial cells and various organs [ 23 28 ]. The main parasite ligand for the IE adhesion is a family (∼60 members) of PfEMP1 pro teins [29 31 ] that are expressed on the surface of IEs in specialized structures called knobs [32] . No parasite co receptor molecules required for the IE adhesion have Role of IE cytoadhesion mediated by the interactions of PfEMP1 proteins with host receptors in the pathology of malaria and its implications for anti adhesion therapy been discovered so far. PfEMP1 proteins are coded by var genes. Mature parasite expresses on the surface the prod uct of only one of the var genes [33] , but can switch to another variant, thus changing its antigenic and adhesion phenotype [30, 34] (figure). Each PfEMP1 protein con sists of one intracellular, one trans membrane, and sever al extracellular domains (∼30 45 kDa, 2 to 7 domains per protein) heavily cross linked by disulfide bonds [31, 35] . These domains have been classified using Greek letters for classes and numbers for sub classes into Duffy bind ing like (DBL) domains (α, β, γ, δ, ε, ζ, Χ) and cysteine rich interdomain regions (CIDRs) (α, β, and γ) [31, 35, 36] . All DBL domains have a similar scaffold [37 40] , and the C terminal part of the CIDR scaffold is sim ilar to the C terminal part of the DBL domain [41] . These domains are responsible for the adhesion to various host receptors (reviewed in [42] ), each domain represent ing a functional binding (with higher or lesser efficiency) unit. The specificity and combination of these domains in the expressed PfEMP1 may determine the final IE adhe sion specificity, strength of binding, and, possibly, disease pathology [43] . We have cloned and expressed a library of PfEMP1 constructs (n > 180) that contained all domains (n = 272) or domain tandems (for example, many DBL domains are followed by the CIDR domains) from all PfEMP1 proteins (n = 59) from the NF54 parasite line, in their functional (receptor binding) form, as has been demonstrated in a number of our publications [11, 44 49] . This proteome wide collection of PfEMP1 con structs is an important tool for identification of various novel receptor domain pairs and screening for anti adhe sion compounds against different binding IE specificities. Although the members of the PfEMP1 family belong to the variable class proteins (the sequences vary from para site to parasite in the field), such variability may be not an insurmountable problem, as we discuss below.

As we mentioned above, cytoadhesion of IEs is either a cause or a prerequisite for SM, including CM [5 7, 27] and PM [4, 50] . The most studied syndrome is PM. Only one member of the PfEMP1 family, VAR2CSA, is involved in PM [ 51 53 ]. It has a characteristic sequence of three DBL X domains followed by three DBLε domains. This architecture of VAR2CSA is conserved in all studied P. falciparum strains. Anti adhesion antibod ies, that appear after one or two successive pregnancies in malaria endemic regions, alleviate PM by inhibiting IE binding to the CSA receptor in the placenta [54] . Common drugs are not particularly effective in the pre vention of PM and might be even harmful [13] . In light of this, a drug that does not penetrate cell membranes and, consequently, mother and fetus tissues, but interferes with the parasite adhesion (the key event in PM) would be par ticularly safe for the use in pregnant women.

As has been shown by us and other researchers, women that acquire resistance to pregnancy malaria, develop anti bodies to VAR2CSA over successive pregnancies [44, 50] . Identification of a monoclonal antibody inhibiting the binding of several strains of PM parasites to the host ligand CSA indicates that the conserved features of these variable proteins are sufficient to provide a wide cross strain effec tiveness [55] . Such conserved structures of the VAR2CSA domains could be the targets for anti adhesion compounds through the competitive or allosteric mode of action.

The main candidate for the host adhesion receptor in CM is ICAM 1 [6, 7, 27, 56] . However, it was suggested recently that PfEMP1 proteins containing a tandem of domains biding to ICAM 1 and endothelial protein C receptor (EPCR) are involved predominantly in CM pathogenesis [57, 58] , potentially binding to one or both receptors [59, 60] . Only six DBLβ domains (out of more than 250 domains from ∼60 PfEMP1 proteins) in P. falci parum IT4 strain have been identified as capable of bind ing to ICAM 1 [61] , as well as only two DBLβ domain in the 3D7 strain [11, 62] . Similarly, only a limited set of domains in each genome variant bound EPCR [63, 64] . The fact that only a small number of PfEMP1 domains strongly bind to either of these receptors fits well with the epidemiology of CM, which is a rare but extremely dead ly SM syndrome. Extensive epidemiological data [65, 66] support the hypothesis that only a limited number of par asite lines, possibly expressing particular variants of PfEMP1 (and containing particular domains), may be the source of severe disease, as it happens in PM.

Several studies have clearly demonstrated that IE cytoadhesion directly affects vascular inflammation and endothelial dysfunction [67, 68] . Vascular inflammation contributes to the disease severity [69] , plays a key role in CM and PM, and is characterized by induction of adhe sion molecules (e.g., ICAM 1) and pro inflammatory cytokines, as well as by vascular permeability caused by the disruption of the endothelial barrier integrity [70 72 ]. Some of these inflammatory processes are initiated and stimulated by direct interactions between PfEMP1 domains and host receptors through a complex intracel lular signaling networks [25, 26] . Consequently, anti adhesion drugs that prevent or reverse these interactions may reduce inflammation, thus contributing to a better outcome of SM syndromes. Our recent preliminary results demonstrate that the anti adhesion treatment may reduce vascular inflammation, although further studies on this topic are required to support this observation.

The sequences of PfEMP1 family members signifi cantly vary in the field. Nevertheless, this variability does not preclude specific groups of domains from binding to the corresponding conserved receptors. This was corrob orated by the recent structural study that revealed con served binding pockets in variant PfEMP1 domains that bind to the conserved receptors [14] . In this regard, all DBL and CIDR domains have a similar scaffold [37 41 ]. Theoretically, molecules that mimic the binding motifs of host receptors might be effective against multiple variants of relevant PfEMP1 proteins, as demonstrated for the small molecule that mimics the ICAM 1 loop and inhibits the binding of two parasite variants to the ICAM 1 receptor [73] . However, these types of anti adhesion molecules might be problematic, since they may compete with the natural ligands of these receptors and produce harmful side effects. Therefore, molecules that bind directly to variable PfEMP1 domains and inhibit their binding to the specific receptors would be preferable. The above mentioned structural study [14] strongly supports the idea of inhibiting the binding of variant domains to the corresponding receptor via interaction between a sin gle molecule and the receptor binding conserved pocket in the protein.

Importantly, the available data support the idea that the diversity of variants involved in SM cases is also sig nificantly restricted. In malaria endemic areas, SM accounts for <2% of total malaria cases in young children and predominantly occurs only once or twice in a life time [65] . This indicates that the broad immunity against SM develops quickly in early childhood [66] despite vari ations in the IE surface proteins. The existence of a mon oclonal antibody that inhibits the binding of several preg nancy malaria parasite strains to the host ligand chon droitin sulfate A (CSA) [55] further indicates that the conserved features of PfEMP1 proteins might be suffi cient to provide the cross strain effectiveness of anti adhesion molecules. Hence, a single adhesion inhibiting molecule might exhibit cross strain/PfEMP1 activity for a particular host receptor.

Direct screening of live laboratory or field isolates for identification of agents that would inhibit parasite adhe sion to different host receptors is an extremely slow and tedious process not currently amenable to the use of high throughput (HT) protocols due to technical and biologi cal limitations. Our two step approach to identification of anti adhesion molecules overcomes these limita tions [47] . Moreover, it was designed to screen mixture based libraries to allow fast deconvolution to individual active compounds in a few steps, because the first HT step is performed in vitro. Testing the sets of such compounds for the inhibition of live parasite binding is not feasible due to the toxic effects of these mixtures or of the solvent dimethyl sulfoxide (DMSO, tolerated up to 20% in our in vitro system), as well as due to the low throughput of live parasite assays.

First, mixture based libraries of small molecules are screened and deconvoluted to single compounds in a HT testing for the inhibition of interactions between known host receptors involved in IE adhesion and various rele vant PfEMP1 domains immobilized on BioPlex beads (Bio Rad, USA). Second, molecules identified in the first step are validated for the adhesion inhibiting activity using live heterologous IEs. The use of heterologous IEs, preferably from distant geographical regions, is important to demonstrate that identified anti adhesion drugs inhib it the binding of IEs with diverse genetic background and are not specific to a single line only. Since the number of hits to test with IEs is low, the two step procedure pro vides HT identification of anti adhesion molecules.

ChemBridge library. The development and proof of principle of our HT approach for the screening of anti adhesion molecules have been performed [47] using a subset (n = 10,000) of the DIVERSet small molecule library from the ChemBridge Corporation. This library was selected based on its commercial availability, substan tial size appropriate for identification of a sufficient num ber of active molecules, possibility to purchase separate subsets at affordable price for the initial development, as well as required physicochemical and pharmacological characteristics reflected in multiple publications. These characteristics include broad biologically relevant phar macophore diversity space. For example, 50,000 drug like small molecules of the DIVERSet library cover 60% of the total 3 point pharmacophore space of the entire EXPRESS Pick™ Collection (internal) consisting of 500,000 compounds.

Before working with the small molecule libraries, we demonstrated the feasibility of our two step approach using antibodies that inhibited the binding of three recep tors, CD36 (the most common IE binding receptor), CSA (receptor involved in PM), and ICAM 1 (receptor involved in CM) and erythrocytes infected with parasite lines binding to these receptors. When using PfEMP1 domains binding to these receptors and the correspon ding binding parasite lines, we found a remarkable con cordance between the in vitro molecular Bio Plex assays and assays with live IEs, which strongly supported the fea sibility of our two step approach for screening anti adhe sion molecules. Since physical principles and readouts of the assay are the same for large (antibodies) and small anti adhesion molecules, we expected to get similarly concordant results using the same two step approach and small molecule libraries.

As the first step, we used a sub library of 10,000 compounds to prepare 125 pools, each containing 80 compounds (125 μM solution of each compound in DMSO) for the initial screening. In this way, the initial screening of all 10,000 compounds required less than two 96 well plates to assess their inhibitory effect on the bind ing of each of three endothelial receptors to the corre sponding PfEMP1 domains.

We chose 75% inhibition of binding as an arbitrary threshold for our in vitro assay. Five different CD36 bind ing domains were selected for the screening of the CD36 binding inhibition. Interestingly, we did not find mixtures that inhibited CD36 binding over the selected threshold and, consequently, did not pursue further deconvolution. It is likely that identification of more efficient compounds for the inhibition of CD36 binding requires a larger library. For two other receptors (CSA and ICAM 1) and the corresponding three CSA binding domains and one ICAM 1 binding domain (the only one identified by us in the NF54 line), we successfully identified inhibitory mixtures and deconvoluted them to three and two active individual compounds, respectively. Moreover, out of three compounds that inhibited the binding of the CSA binding domain to CSA, two compounds shared the same sulfonyl containing primary scaffold, which further strengthened the feasibility of our approach.

Using the in vitro assay, we demonstrated that the IC 50 values for both receptors were in a low micromolar range: 1.73 μM for the full length VAR2CSA PfEMP1 protein that contained six CSA binding domains [47] , and 18 μM for the ICAM 1 binding domain PF11_0521 DBL2β3. The latter binds ICAM 1 receptor with a very high avidity (∼2 nM) [46, 59] . Therefore, identification of small molecular compounds that can compete in the domain-receptor interactions at low micromolar con centration is an important step toward identification of more potent compounds.

In accordance with our two step approach, we demonstrated that compounds identified in our first in vitro step inhibited the binding of live IEs. In these experiments, which were performed at a single compound concentration of 100 μM as a proof of principle, we used the CS2 (CSA binding) and 3G8 (ICAM 1 binding) par asite lines [74] . These lines have originated from a com pletely different genetic and geographic background (IT4 line from South East Asia [75] ) than the NF54 line (from Africa [76] ) that was used as a source of our recombinant receptor biding domains for the in vitro assays. Our experiments with live IEs clearly demonstrated that the identified active compounds inhibited the binding of CS2 and 3G8 lines to the corresponding binding receptors. This was a very important finding as it indicated that small molecule inhibitors may overcome a challenge pre sented by the domain diversity and can inhibit the bind ing of IEs of different genetic origin. Moreover, for the CS2 line, the identified compounds not only blocked, but also reversed the established interactions between IEs and CSA. This is also an extremely important feature, as reversing the established sequestration might have a sig nificant impact on the SM pathology due to the removal of already sequestered parasites contributing significantly to the vascular inflammation.

Therefore, by using a subset (10,000 compounds) of the DIVERSet library, we not only successfully developed a two step screening procedure, but identified three com pounds that inhibited IE adhesion to the CSA receptor and two compounds that inhibited IE adhesion to the ICAM 1 receptor -two principal receptors involved in the sequestration of IEs in PM and CM [47] . This indi cates that screening of currently commercially available full DIVERSet collection of small molecules from ChemBridge (n = 150,000) may reveal up to 30 50 indi vidual active compounds/hits to select for the best leads based on their activity, cellular and animal toxicity, and pharmacokinetics/pharmacodynamics (PK/PD) in order to further develop them into anti adhesion drugs.

Natural product library (conopeptides). Other libraries may provide an additional opportunity for screening for anti adhesion compounds. In this respect, collections of natural products might be a good source for this type of screening. As a proof of principal, we used [77] a library of conotoxins/conopeptides, which are compounds expressed in the venom of marine mollusks belonging to the Conus genus. There are hundreds of thousands of these novel compounds, mostly disulfide rich and well structured peptides, expressed by more than 850 species of Conus mollusks [ 78 80] . Their presence in the venoms of mollusks does not necessarily mean that they all are toxic or harmful for humans. In addition, they can be modified to abolish the toxicity, while preserving their biological activity [81] . This class of molecules is actively pursued for the discovery of novel drugs to treat various diseases [82] .

The high specificity and affinity of conotoxins for many ubiquitous somatic receptors suggest that they might be powerful compounds to prevent or reverse inter actions between domains of malaria adhesins, PfEMP1 proteins, and host receptors involved in SM. In our work [77] , we extracted venom samples from 460 speci mens of Conus nux and fractionated them by size exclu sion (SE) high performance liquid chromatography (HPLC), followed by reverse phase (RP) HPLC. The obtained fractions were tested for the inhibition of bind ing between three vascular receptors (CD36, CSA, and ICAM 1) and the corresponding receptor binding PfEMP1 domains immobilized on BioPlex beads using the above described in vitro approach [47] . Remarkably, six individual C. nux venom fractions, which contained either single peptides or a very limited set of peptides, affected the binding of several domains with different receptor specificity to the corresponding receptors, including proteins CD36 and ICAM 1 and polysaccha ride CSA. These results suggest that either the peptides in these fractions bind to common structural elements in different PfEMP1 domains with a similar general scaffold (as we discussed above) or a few different peptides in the fraction interact with different domains (or receptors) and block the domain-receptor interactions. The ability of conotoxin fractions to inhibit the binding of IE adhesins with multiple binding specificity to a broad set of receptors can be extremely useful in the development of efficient and safe anti adhesion drugs against SM [15, 16] , because IEs isolated from SM patients often bind multiple receptors [57, 83] . Therefore, natural prod ucts, such as conopeptides, might be a promising source of anti adhesion compounds that can be used for identi fication of leads for their development into anti adhesion anti malarial drugs.

TPIMS libraries. The above results demonstrate that screening of large libraries may provide a sufficient num ber of hits with low IC 50 values for their development into leads and, further, into anti adhesion drugs; and that peptides and peptidomimetics might be extremely useful classes of molecules to identify these leads. Such large mixture based libraries, ideally suitable for our two step approach, have been developed at the Torrey Pines Institute for Molecular Studies (TPIMS) in a very con venient format allowing analysis of millions of com pounds using just hundreds to thousands of samples [84 86 ]. The principle of this method is in the preparation of positional scanning libraries, each representing a differ ent scaffold with several replacement groups, using the tea bag approach [87] . The sub libraries of each scaffold have one fixed (defined) replacement group and combi nations of other replacement groups. The number of these sub libraries is equal to the number of variants for the replacement groups. Analysis of screening results allows identification of the most active replacement groups. Then, a new sub library(s) containing all combi nations of these most active groups is prepared and tested for its activity. In 2 3 iterations (depending on the com plexity of the initial library), a library of individual com pounds is prepared based on the activity of mixtures with the defined replacement groups, and the most active indi vidual compounds are identified. As we mentioned above, the screening of mixture based libraries requires consid erably less effort, time, and resources compared to the traditional HT screening of individual compounds.

TPIMS libraries only partially overlap with the struc tural space of currently approved drugs and, therefore, further add to the molecular complexity of libraries com monly used in HT screening [88, 89] and expand the tra ditional relevant space of medicinal chemistry [89] . In addition, large mixture based libraries designed around a limited number of molecular scaffolds provide an oppor tunity for rapid elucidation of the structure-activity rela tionships (SARs) during screening. TPIMS collection is characterized by a larger degree of molecular complexity and larger 3D conformational space than typically avail able commercial collections [88] and possesses the drug like properties similar to the property space of known drugs [89] . Successful application of TPIMS library col lection in preclinical and clinical studies has been exten sively reviewed [85, 90] .

In our work [91] , we screened a collection of TPIMS libraries consisting of more than 30 million compounds designed around 75 molecular scaffolds in order to iden tify the hits against binding between ICAM 1 (involved in CM) and the corresponding binding domain PF11_0521 DBL2β3 from the 3D7 line PfEMP1 protein [11, 46, 47] , with IC 50 in a nanomolar range.

Based on the initial screening, dithiazole Positional Scanning Synthetic Combinatorial Library (TPI 2103, 3990 compounds) with the highest inhibitory activity and lowest complexity (two replacement groups) was selected for positional scanning deconvolution of the binding inhibiting compounds. Individual compounds (104 in total) derived from the deconvolution of TPI 2103 repre sented all combinations of the selected most active R1 and R2 replacement groups. Their testing revealed two compounds (2648 40 and 2648 33) that inhibited ICAM 1 binding by more than 50% at 1 μM concentration. These two compounds were then characterized at a range of concentrations for the inhibition of ICAM 1 binding (i) in vitro using the bead immobilized domain and (ii) with live erythrocytes infected by heterologous ICAM 1 binding 3G8 parasite line, as well as for cyto toxicity against two human cell lines.

The two compounds had the IC 50 values of 362 nM (2648 40) and 696 nM (2648 33) in vitro, which was about 50 and ∼25 times, respectively, better than for the compounds identified in our previous work with the small size ChemBridge sub library [47] . Importantly, their inhibitory activity with live IEs was similar (IC 50 of 352 nM and 669 nM for 2648 40 and 2648 33, respec tively). Thus, the same compound provided stronger inhi bition of ICAM 1 binding on the beads and of binding between IEs and surface immobilized ICAM 1, which was in accordance with our previous observations in [47] . Furthermore, the ICAM 1 binding domains of the PfEMP1 protein expressed on the surface of erythrocytes infected with NF54 line (used in in vitro experiments) and 3G8 line (used in experiments with live IEs) significantly differed in their amino acid sequence (44% identities, 55% positives, and 15% gaps by BLAST). Nevertheless, active compounds identified using a particular genetic background in the in vitro assays were successful in inhibiting the binding of live IEs of very different genetic background, which again corroborated our results obtained using completely different compounds [47] . We believe that our approach might be universally employed for identification of anti adhesion compounds against various receptor-domain pairs despite a substantial diversity of PfEMP1 domains/proteins.

The cytotoxicity studies demonstrated the selectivity index (SI, ratio of 50% cytotoxic concentration (CC 50 ) toward human cell lines to 50% binding inhibiting con centration (IC 50 ) between the surface immobilized receptors and live IE) of ∼70 and ∼37 for the two com pounds, respectively. This is an excellent result, as SI > 10 is considered the minimally acceptable value and SI > 50 is an ideal value for the target candidate profile (TCP 1) [48] , because after getting into the bloodstream, com mon malaria parasite killing drugs should cross at least 3 membranes (red blood cell membrane, parasitophorous vacuole membrane, and parasite plasma membrane) for their effect. The anti adhesion drugs are supposed to work immediately at the outer surface of IEs after enter ing the blood. Therefore, the two identified lead com pounds provide an excellent starting point for the devel opment of anti adhesion drugs against SM and CM, in which IE adhesion to ICAM 1 receptor plays an extreme ly important pathological role.

As we mentioned above, the binding to ICAM 1 and EPCR is implicated in the development of SM and CM. Many parasites isolated from SM or CM patients demon strated the presence of a tandem of ICAM 1 and EPCR binding domains in the expressed PfEMP1 molecules [59, 60, 92 96] . Even if both these domains in a tandem are required for the development of SM and/or CM, this does not mean that the drugs should inhibit the binding of both domains to the corresponding receptors to success fully block IE sequestration. In this case, inhibition of ICAM 1 binding only may significantly reduce the effica cy of IE sequestration, especially in the brain microvascu lature, where EPCR is expressed at low levels, while the content of ICAM 1 is high and further increases during brain inflammation (reviewed in [97] ), in particular, dur ing CM associated inflammation induced by TNFα (reviewed in [98] ). In this respect, identification of other compounds that will not only prevent but also reverse ICAM 1 sequestration, may have a significant advantage in the anti adhesion adjunct treatment. As demonstrated in our studies and works of other authors, ICAM 1 binds to the ICAM 1 binding DBL domains with an extremely high avidity (2 4 nM) [46, 59] . Therefore, identification of such compounds might not be a trivial task. Most like ly, they will have an allosteric, and not competitive mode of action. The leads identified in [47, 91] did not reverse the established ICAM 1-domain interactions. Hence, molecules with this activity are still to be discovered. Nevertheless, just inhibition of ICAM 1 binding might be sufficient to reduce or prevent the development of pathologies related to the continuous IE sequestration in SM or CM, although this hypothesis should be clarified experimentally.

Since anti adhesion drugs do not usually kill malaria parasites (if they did, this would be an additional impor tant bonus), it is difficult to justify their trials in human patients with severe forms of malaria. One of the effects these drugs should produce is reduction of inflammation of endothelial cells (ECs) by preventing or reversing IE cytoadhesion. This can be studied in vitro by incubation of ECs with IEs that can adhere to these cells [for exam ple, CSA binding IEs and human trophoblast derived BeWo cells expressing CSA, or ICAM 1 binding IEs and TNFα stimulated human umbilical vascular endothelial cells (HUVEC) that express ICAM 1] in the presence and absence of anti adhesion compounds, followed by detection of inflammatory molecules secreted by the cells. However, these effects are not easy to demonstrate in vivo in the preclinical studies, as no appropriate animal model for P. falciparum malaria is available. PfEMP1 pro teins are specific for P. falciparum only, while malaria par asite species that infect rodents are very different and do not share homologous PfEMP1 proteins. Even human ized mouse malaria model [99] , in which immunodefi cient laboratory NOD scid gamma (NSG) mice are injected with human erythrocytes for several days to sub stitute mouse erythrocytes and then challenged with P. falciparum to establish the infection, will not be appro priate, as mouse endothelial receptors, though homolo gous, are different from the human receptors interacting with PfEMP1 proteins and may not provide adequate IE cytoadhesion. Therefore, appropriate models should be designed for testing anti adhesion compounds (beyond their cellular, animal, and human cytotoxicity) before moving to trials in humans. Potentially, some non human primate models, like P. falciparum infection of Aotus monkeys [100] , may be used to test IE sequestration and activity of anti adhesion drugs.

The two step approach developed by us for the HT identification of anti adhesion compounds might be use ful in the identification of compounds for treatment of other diseases, for which interactions between two known molecules/molecular structures play an important role in the disease pathology, e.g., infection of cells by viral, par asitic, or bacterial pathogens through specific receptors.

Identification of anti adhesion compounds from large libraries via HT screening in vitro followed by their in vivo or ex vivo testing may significantly speed up the discovery of novel therapeutics for various diseases.

World malaria report

Continued cytoadherence of Plasmodium falciparum infect ed red blood cells after antimalarial treatment

Cytoadherence, in: Encyclopedia of Malaria (Hommel, M., and Kremsner

Adherence of Plasmodium falciparum to chondroitin sulfate A in the human placenta

Malaria pathogenesis

Receptor Specific Adhesion and Clinical Disease in Plasmodium falciparum

An immunohistochemical study of the pathology of fatal malaria. Evidence for wide spread endothelial activation and a potential role for inter cellular adhesion molecule 1 in cerebral sequestration

Antibodies that inhibit Plasmodium falciparum adhesion to chondroitin sulfate a are associated with increased birth weight and the gesta tional age of newborns

Maternal malaria and par asite adhesion

Multilaboratory approach to pre clinical evaluation of vaccine immunogens for placental malaria

High throughput function al assays of the variant antigen PfEMP1 reveal a single domain in the 3D7 Plasmodium falciparum genome that binds ICAM1 with high affinity and is targeted by naturally acquired neutralizing antibodies

Gamma globulin and acquired immunity to human malar ia

Competitive facil itation of drug resistant Plasmodium falciparum malaria parasites in pregnant women who receive preventive treat ment

The structural basis for CD36 binding by the malaria parasite

Modulation of malaria virulence by determinants of Plasmodium falci parum erythrocyte membrane protein 1 display

Rosette disrupting effect of an anti plasmodial compound for the potential treatment of Plasmodium falciparum malaria complications

A human 88 kD membrane gly coprotein (CD36) functions in vitro as a receptor for a cytoadherence ligand on Plasmodium falciparum infected erythrocytes

Intercellular adhesion mole cule 1 is an endothelial cell adhesion receptor for Plasmodium falciparum

Role of glycans in Plasmodium falci parum infection

Rosetting: A new cytoadherence property of malaria infected erythrocytes

Uninfected erythrocytes form "Rosettes" around Plasmodium Falciparum infected erythrocytes

Clinical significance of sequestra tion in adults with severe malaria

Induction of pro inflammatory response of the placental trophoblast by Plasmodium falciparum infected erythrocytes and TNF

Plasmodium falciparum para sitized red blood cells modulate the production of endothe lin 1 by human endothelial cells

Src family kinase signaling modulates the adhesion of Plasmodium falciparum on human microvascular endothelium under flow

Plasmodium falciparum Intercellular adhesion molecule 1 based cytoadherence related signaling in human endothelial cells

Breaking down the blood-brain barrier: signaling a path to cerebral malaria?

Signal transduction in plasmodium-red blood cells inter actions and in cytoadherence

The large diverse gene family var encodes proteins involved in cytoadherence and anti genic variation of Plasmodium falciparum infected erythro cytes

Switches in expression of Plasmodium falciparum var genes correlate with changes in antigenic and cytoadherent phenotypes of infected erythro cytes

Genome sequence of the human malaria parasite Plasmodium falciparum

Knob independent cytoadher ence of Plasmodium falciparum to the leukocyte differenti ation antigen CD36

Antigenic variation in Plasmodium falciparum

Rapid switching to multiple anti genic and adhesive phenotypes in malaria

Identification of a Plasmodium falci parum intercellular adhesion molecule 1 binding domain: A parasite adhesion trait implicated in cerebral malaria

Plasmodium falci parum erythrocyte membrane protein 1 diversity in seven genomes -divide and conquer

The crystal structure of P. knowlesi DBPalpha DBL domain and its implications for immune evasion

Structural basis for Duffy recognition by the malaria parasite Duffy binding like domain

The structure of a chondroitin sul fate binding domain important in placental malaria

Structure of the DBL3x domain of preg nancy associated malaria protein VAR2CSA complexed with chondroitin sulfate A

The cysteine rich interdomain region from the highly variable plasmodium falciparum erythro cyte membrane protein 1 exhibits a conserved structure

Disguising itself -insights into Plasmodium falciparum binding and immune evasion from the DBL crystal struc ture

Host response to cytoadherence in Plasmodium falciparum

Effects of sex, parity, and sequence variation on seroreactivity to candidate pregnan cy malaria vaccine antigens

A plasma survey using 38 PfEMP1 domains reveals frequent recognition of the Plasmodium falciparum antigen VAR2CSA among young tanzanian children

Structure-function-immuno genicity studies of PfEMP1 domain DBL2beta PF11_0521 , a malaria parasite ligand for ICAM 1

High throughput screening platform identifies small molecules that prevent sequestra tion of Plasmodium falciparum infected erythrocytes

Plasmodium falciparum infected erythrocytes can bind to host receptors integrins alphaVbeta3 and alphaVbeta6 through DBLdelta1_D4 domain of PFL2665c PfEMP1 protein

Comprehensive analysis of Fc mediated IgM binding to the Plasmodium falciparum erythrocyte membrane protein 1 family in three parasite clones

Evidence for the involvement of VAR2CSA in pregnancy associated malaria

Selective upregulation of a single dis tinctly structured var gene in chondroitin sulphate A adhering Plasmodium falciparum involved in pregnancy associated malaria

Disruption of Var2csa gene impairs placental malaria associated adhesion phenotype

VAR2CSA is the principal ligand for chondroitin sulfate A in two allogeneic isolates of Plasmodium falciparum

Maternal antibodies block malaria

Human monoclonal IgG selection of Plasmodium falciparum for the expression of placental malaria specific variant surface antigens

Specific receptor usage in Plasmodium falciparum cytoadherence is associated with disease outcome

Parasites caus ing cerebral falciparum malaria bind multiple endothelial receptors and express EPCR and ICAM 1 binding PfEMP1

Loss of endothelial protein C receptors links coagulation and inflammation to parasite sequestration in cerebral malaria in African children

Structure guided identification of a family of dual receptor binding PfEMP1 that is associated with cerebral malaria

Interaction between endothelial pro tein C receptor and intercellular adhesion molecule 1 to mediate binding of Plasmodium falciparum infected ery throcytes to endothelial cells

Mapping a common inter action site used by Plasmodium falciparum Duffy binding like domains to bind diverse host receptors

A novel domain cassette identifies Plasmodium falciparum PfEMP1 proteins binding ICAM 1 and is a target of cross reactive, adhesion inhibitory antibodies

EPCR and malaria severity: The center of a perfect storm

The role of PfEMP1 adhesion domain classification in Plasmodium falciparum pathogenesis research

Parasite burden and severity of malaria in Tanzanian children

Clinical and parasitological studies on immunity to Plasmodium falciparum malaria in children, Scand

Cerebral Plasmodium falciparum malaria: The role of PfEMP1 in its pathogenesis and immunity, and PfEMP1 based vaccines to prevent it

Blood-brain barri er in cerebral malaria: Pathogenesis and therapeutic inter vention

Piecing together the puzzle of severe malaria

Blood coagulation, inflammation, and malaria, Micro circulation

Endothelial activation and dysregulation in malaria: a potential target for novel therapeutics

A unified hypothe sis for the genesis of cerebral malaria: sequestration, inflammation and hemostasis leading to microcirculatory dysfunction

Rational design of anticytoadher ence inhibitors for Plasmodium falciparum based on the crystal structure of human intercellular adhesion molecule 1

Investigating the host binding signature on the Plasmodium falciparum PfEMP1 protein family

Recombination hotspots and population struc ture in Plasmodium falciparum

A barcode of organellar genome polymorphisms identifies the geographic origin of Plasmodium falciparum strains

Conus venom fractions inhibit the adhesion of Plasmodium falciparum erythrocyte mem brane protein 1 domains to the host vascular receptors

Conotoxins: Chemistry and biology

ConoServer: Updated content, knowledge, and dis covery tools in the conopeptide database

Discovery methodology of novel conotoxins from Conus species

Drugs from Slugs. Part II -Conopeptide bioengineering

Human health and snails

Fresh isolates from children with severe Plasmodium falciparum malaria bind to multiple receptors

Strategies for the use of mixture based synthetic combinatorial libraries: scaffold ranking, direct testing in vivo, and enhanced deconvolution by computational methods

Selective agonists and antagonists of formylpeptide receptors: duplex flow cytom etry and mixture based positional scanning libraries

Identification of two novel, potent, low liability antinociceptive compounds from the direct in vivo screening of a large mixture based combina torial library

Tea Bag Synthesis of Positional Scanning Synthetic Combinatorial Libraries and Their Use for Mapping Antigenic Determinants

Expanding the medici nally relevant chemical space with compound libraries

Chemoinformatic analysis of combinatorial libraries, drugs, natural products, and molecular libraries small molecule repository

Scaffold ranking and positional scan ning utilized in the discovery of nAChR selective com pounds suitable for optimization studies

Small molecule compounds identified from mixture based library inhibit binding between plasmodium falciparum infected erythrocytes and endothelial receptor ICAM 1

Severe malaria is associated with parasite binding to endothelial protein C receptor

Linking EPCR binding PfEMP1 to brain swelling in pediatric cerebral malaria

Natural and vaccine induced acquisition of cross reactive IgG inhibiting ICAM 1 specific binding of a Plasmodium falciparum PfEMP1 subtype associated specifically with cerebral malaria

Binding hetero geneity of Plasmodium falciparum to engineered 3D brain microvessels is mediated by EPCR and ICAM 1, mBio

Cerebral malaria is associated with differential cytoadherence to brain endothelial cells

The adhesion molecule ICAM 1 and its regulation in relation with the blood brain barrier

Tumor necrosis factor alpha in the pathogenesis of cerebral malaria

Improved murine model of malar ia using Plasmodium falciparum competent strains and non myelodepleted NOD scid IL2Rgamma null mice engrafted with human erythrocytes

Infections with Plasmodium falci parum and Plasmodium vivax in the owl monkey -model systems for basic biological and chemotherapeutic studies